BLLNNMSHealthcare·Diagnostics & Research#20 in industry

BillionToOne, Inc.

Reports in 9d· 2026-05-06

-5.0% · 90d

$81.76

-2.98 (-3.52%)

News

(2)

April 2026

Apr 21, 20261 week agoARSHealthcare

BLLN Cannot Summarize Filing Due To Missing Source Document Text

BLLNBillionToOne, Inc.

I appreciate you providing the filing details for BillionToOne, Inc. (BLLN). Based on the data provided, the filing structure and metadata are present, but the actual content of the document (the PDF text) is missing. Therefore, I cannot generate the financial analysis or explanatory summary, as al

Read summaryView on SEC EDGAR

Apr 21, 20261 week agoDEF 14AHealthcare

BillionToOne outlines 2026 director votes and executive compensation for shareholders

BLLNBillionToOne, Inc.

# 📜 What This Document Is 🗳️ This document is a **Definitive Proxy Statement (DEF 14A)**. Simply put, it is a massive, formal instruction manual that the company provides to its shareholders before an annual meeting. Its purpose is to inform you about what business will be conducted, who you are

Read summaryView on SEC EDGAR

Key Data

Market Cap$3.76B

Open$84.99

Prev Close$84.74

Day Range$81.65 – $86.60

52W Range$61.96 – $138.70

Volume232,489

P/E (TTM)584.00

EPS$0.14

Dividend Yield—

Beta—

Profit Margin0.96%

Revenue Growth113.10%

Price Target$116.71(+42.8%)

Next Earnings2026-05-06(9d)

Analyst Ratings

Strong Buy8 analysts

Buy 6Hold 2Sell 0

About

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Healthcare · Diagnostics & Research

713 employees

www.billiontoone.com